Adare Pharma Solutions
Adare Pharmaceuticals is a technology-driven CDMO providing product development through to commercial manufacturing expertise focused on oral dosage forms. Adare’s proprietary technology portfolio encompasses ODT’s, taste masking and customised drug release.
Adare Pharma Solutions is a global technology-driven specialty CDMO providing turnkey product development through to commercial manufacturing expertise focused on oral dosage forms for the pharmaceutical market. Adare’s proprietary technology platforms specialise in ODTs, taste masking and customised drug release.
Adare Pharma Solutions rebranded from Adare Pharmaceuticals in September 2020 when it was acquired by private equity firms Thomas H Lee Partners and Frazier Healthcare Partners. Earlier in 2020, Adare acquired Orbis Biosciences, broadening its oral delivery technology portfolio and also moving into the field of injectables for the first time.
Adare was formed in 2015 when TPG Capital acquired and renamed Aptalis, but the company has 30 years of proven legacy with roots in companies such as Eurand and Aptalis. Adare has multiple facilities in the US and Europe, and has developed and manufactured more than 40 products sold by partners in more than 100 countries globally.